Latest News

The Wall Street Journal: Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say


Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to people familiar with the matter.

The Wall Street Journal reported earlier this month that Merck MRK aimed to agree on a purchase of the cancer biotech within a few weeks, a plan that has since been delayed, the people said.


Elon Musk doesn’t have ‘a leg to stand on’: veteran tech analyst

Previous article

The Wall Street Journal: Elon Musk responds to Twitter’s lawsuit, opposing company’s request for expedited trial

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Latest News